CARM: Carisma Therapeutics, Inc.
About
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.
Current Value
$0.871 Year Return
Current Value
$0.871 Year Return
Key Details
Market Cap
$36.20M
P/E Ratio
-0.56
1Y Stock Return
-64.46%
1Y Revenue Growth
90.67%
Dividend Yield
246.74%
Price to Book
-3.3
Strategies that include CARM
Stock's related to CARM
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BLFS | 43.13% | $1.04B | +64.64% | 0.00% |
| HCAT | 36.97% | $458.79M | 0.00% | 0.00% |
| FRST | 35.80% | $302.36M | +21.93% | 3.29% |
| FLIC | 35.64% | $312.91M | +21.97% | 6.05% |
| LXRX | 35.61% | $318.44M | -18.44% | 0.00% |
| QTRX | 35.23% | $424.47M | -53.12% | 0.00% |
| CION | 35.02% | - | - | 12.14% |
| GEO | 34.65% | $3.97B | +204.07% | 0.00% |
| IOVA | 34.34% | $2.50B | +58.41% | 0.00% |
| AMPY | 34.17% | $260.89M | +7.01% | 0.00% |
| CSTL | 34.03% | $808.57M | +48.97% | 0.00% |
| PGEN | 33.99% | $228.91M | -28.00% | 0.00% |
| SWTX | 33.79% | $2.82B | +79.34% | 0.00% |
| CXW | 33.73% | $2.43B | +62.08% | 0.00% |
| OBDE | 33.07% | $1.82B | -2.27% | 4.76% |
| NXDT | 32.46% | $218.01M | -37.42% | 11.58% |
| SAGE | 32.33% | $300.36M | -74.61% | 0.00% |
| EHTH | 32.20% | $143.72M | -37.66% | 0.00% |
| KRYS | 32.02% | $5.12B | +75.65% | 0.00% |
| LXFR | 31.44% | $387.04M | +72.02% | 3.60% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LTRN | -0.01% | $33.22M | -22.61% | 0.00% |
| SOHU | 0.02% | $406.50M | +43.52% | 0.00% |
| CLLS | 0.13% | $141.30M | -30.99% | 0.00% |
| CBOE | -0.14% | $21.46B | +15.84% | 1.11% |
| KSPI | 0.19% | $20.86B | +18.06% | 3.37% |
| GRFS | 0.37% | $2.18B | -11.41% | 0.00% |
| DXYZ | 0.39% | - | - | 0.00% |
| XNET | -0.46% | $123.61M | +26.62% | 0.00% |
| CMG | 0.47% | $80.02B | +33.62% | 0.00% |
| LTM | 0.54% | $8.51B | -100.00% | <0.01% |
| BEEM | -0.56% | $58.36M | -29.34% | 0.00% |
| GL | 0.56% | $9.18B | -8.60% | 0.86% |
| RNR | 0.59% | $13.74B | +23.09% | 0.58% |
| IMRN | -0.67% | $10.31M | -5.04% | 0.00% |
| NKE | 0.69% | $110.02B | -30.63% | 2.01% |
| WHLM | -0.75% | $17.64M | -29.34% | 0.00% |
| LMT | 0.76% | $126.40B | +18.99% | 2.36% |
| CANG | -0.77% | $253.50M | +212.50% | 0.00% |
| GPCR | 0.83% | $1.88B | -36.14% | 0.00% |
| LITB | 1.07% | $35.48M | -75.45% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MSDL | -20.82% | $1.83B | +0.66% | 7.26% |
| MCK | -19.72% | $78.15B | +35.51% | 0.42% |
| COR | -14.88% | $47.48B | +21.20% | 0.86% |
| MANU | -9.34% | $2.88B | -9.41% | 0.00% |
| OXBR | -8.13% | $19.05M | +178.18% | 0.00% |
| CAH | -6.79% | $28.64B | +12.14% | 1.70% |
| SAVA | -6.28% | $1.35B | +25.50% | 0.00% |
| STG | -6.06% | $35.67M | +7.92% | 0.00% |
| CHD | -5.47% | $27.18B | +19.50% | 1.03% |
| ZCMD | -5.31% | $2.80M | -88.67% | 0.00% |
| HUSA | -4.96% | $16.69M | -11.56% | 0.00% |
| PULM | -4.79% | $19.83M | +202.98% | 0.00% |
| CMBT | -4.27% | $2.46B | -29.63% | 13.05% |
| FTNT | -4.15% | $69.59B | +72.67% | 0.00% |
| ORLY | -4.01% | $69.31B | +22.06% | 0.00% |
| HIHO | -4.00% | $8.63M | 0.00% | 6.12% |
| MNOV | -3.97% | $93.19M | +2.15% | 0.00% |
| TKC | -3.80% | $5.80B | +35.51% | 1.30% |
| PGR | -3.61% | $149.10B | +57.29% | 0.45% |
| FAT | -3.54% | $89.30M | -11.53% | 10.73% |
ETF's related to CARM
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| RSPA | 47.98% | $273.87M | 0% |
| PTH | 44.85% | $143.31M | 0.6% |
| GNOM | 44.76% | $70.59M | 0.5% |
| IWC | 44.28% | $933.99M | 0.6% |
| KOMP | 44.26% | $2.09B | 0.2% |
| KCE | 44.08% | $466.96M | 0.35% |
| IBB | 43.64% | $6.66B | 0.45% |
| ARKG | 43.59% | $1.13B | 0.75% |
| PRFZ | 42.62% | $2.65B | 0.39% |
| VTWO | 42.60% | $12.38B | 0.1% |
| ESML | 42.50% | $1.90B | 0.17% |
| IWN | 42.47% | $13.17B | 0.24% |
| IWM | 42.45% | $75.73B | 0.19% |
| SFYX | 42.44% | $105.21M | 0.06% |
| REGL | 42.30% | $1.65B | 0.4% |
| SMMD | 42.09% | $1.24B | 0.15% |
| VXF | 41.80% | $21.54B | 0.06% |
| DON | 41.55% | $3.90B | 0.38% |
| SMMV | 41.54% | $321.07M | 0.2% |
| EES | 41.49% | $668.71M | 0.38% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FMF | 0.20% | $244.61M | 0.95% |
| BOXX | 0.21% | $4.43B | 0.1949% |
| DBO | 0.32% | $217.57M | 0.77% |
| ULST | -0.38% | $535.47M | 0.2% |
| XHLF | 0.43% | $874.27M | 0.03% |
| AGZD | -0.44% | $142.76M | 0.23% |
| UCON | 0.46% | $3.19B | 0.85% |
| HIGH | 0.48% | $302.78M | 0.51% |
| KRBN | -0.63% | $242.47M | 0.85% |
| PREF | 0.67% | $999.92M | 0.55% |
| SGOV | -0.75% | $27.53B | 0.09% |
| TBLL | 0.78% | $1.92B | 0.08% |
| MINT | -0.85% | $11.62B | 0.35% |
| BILZ | 1.32% | $563.02M | 0.14% |
| SOYB | -1.53% | $27.32M | 0.22% |
| HDRO | 1.68% | $164.26M | 0.3% |
| DBE | 1.94% | $50.13M | 0.77% |
| USCI | 1.96% | $185.47M | 1.07% |
| GSG | 1.99% | $914.42M | 0.75% |
| UNG | 2.37% | $908.80M | 1.06% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -29.66% | $388.04M | 1.43% |
| VIXY | -24.06% | $195.31M | 0.85% |
| TAIL | -19.65% | $67.98M | 0.59% |
| DBA | -15.08% | $755.88M | 0.93% |
| USDU | -11.92% | $201.97M | 0.5% |
| UUP | -10.14% | $309.25M | 0.77% |
| CORN | -10.07% | $61.12M | 0.2% |
| KCCA | -7.44% | $220.51M | 0.87% |
| EQLS | -6.81% | $76.08M | 1% |
| CTA | -6.74% | $350.27M | 0.78% |
| TBIL | -6.66% | $4.38B | 0.15% |
| XBIL | -6.28% | $637.70M | 0.15% |
| WEAT | -6.13% | $120.27M | 0.28% |
| SMB | -6.12% | $266.77M | 0.07% |
| KMLM | -5.89% | $353.87M | 0.9% |
| SOYB | -1.53% | $27.32M | 0.22% |
| MINT | -0.85% | $11.62B | 0.35% |
| SGOV | -0.75% | $27.53B | 0.09% |
| KRBN | -0.63% | $242.47M | 0.85% |
| AGZD | -0.44% | $142.76M | 0.23% |
News
Yahoo
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today presented promising preclinical data on engineered macrophages for treating liver fibrosis at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024. These results underscore the pre-clinical efficacy of Carisma's engineered macrophages in multiple liver fibrosis models and offer
Yahoo
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data demonstrated that the development candidate can successfully crea
Yahoo
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended September 30, 2024, and highlighted recent business updates.
Yahoo
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for the treatment of hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data will be presented in a p
Yahoo
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Sohanya Cheng, MBA to the Company's Board of Directors, effective October 31, 2024. Additionally, Michael Torok has informed the Board of his intention to step down as a member, effective October 31, 2024, due to other professional commitments.
Yahoo
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC), taking place in Houston, Texas, November 6 -10, 2024.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.